Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 16:14:1400193.
doi: 10.3389/fonc.2024.1400193. eCollection 2024.

Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review

Jiamin Xu  1 , Shukun Mu  2 , Yun Wang  2 , Suchun Yu  3 , Zhongming Wang  2
Affiliations
Review

Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review

Jiamin Xu et al. Front Oncol. .

Abstract

The incidence of melanoma is increasing year by year and is highly malignant, with a poor prognosis. Its treatment has always attracted much attention. Among the more clinically applied immunotherapies are immune checkpoint inhibitors, bispecific antibodies, cancer vaccines, adoptive cell transfer therapy, and oncolytic virotherapy. With the continuous development of technology and trials, in addition to immune monotherapy, combinations of immunotherapy and radiotherapy have shown surprising efficacy. In this article, we review the research progress of immune monotherapy and combination therapy for advanced melanoma, with the aim of providing new ideas for the treatment strategy for advanced melanoma.

Keywords: combination therapy; immune checkpoint inhibitors; melanoma; oncolytic virus; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. (2022) 144:500–22. doi: 10.5858/arpa.2019-0561-RA - DOI - PubMed
    1. Amalinei C, Grigoraş A, Lozneanu L, Căruntu ID, Giuşcă SE, Balan RA. The interplay between tumour microenvironment components in Malignant melanoma. Medicina (Kaunas). (2022) 58:365. doi: 10.3390/medicina58030365 - DOI - PMC - PubMed
    1. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, et al. . Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. (2021) 611:155–60. doi: 10.1038/s41586-022-05368-8 - DOI - PMC - PubMed
    1. McQuade JL, Homsi J, Torres-Cabala CA, Bassett R, Popuri RM, James ML, et al. . A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer. (2018) 18:1274. doi: 10.1186/s12885-018-5193-9 - DOI - PMC - PubMed

LinkOut - more resources